Rhodiola Rosea as an Adaptogen: Evidence from 26 RCTs on Endurance and Stress
A 2025 meta-analysis pooled 26 randomized trials with 668 participants and found that Rhodiola improves VO2max, time to exhaustion, and reduces markers of muscle damage and oxidative stress. A breakdown of the numbers, mechanism, and limitations.
A meta-analysis of 26 RCTs (668 participants, Wang et al., Frontiers in Nutrition, 2025) showed that Rhodiola significantly improves VO2max (ES=0.32), time to exhaustion (ES=0.38), and reduces post-exercise creatine kinase (ES=−0.84) and malondialdehyde (ES=−1.21). Data were obtained in healthy young adults; mean supplementation duration was 33 days.
What is Rhodiola Rosea and Why Is It Called an Adaptogen?
Rhodiola rosea is a perennial plant of the Crassulaceae family, native to Siberia, Scandinavia, and the mountains of Central Asia. Its primary bioactive compounds are rosavins and salidroside. These are thought to be responsible for the adaptogenic effect: they interact with the hypothalamic-pituitary-adrenal axis, modulating cortisol and catecholamine responses to stress.
The term "adaptogen" refers to a substance that increases the body's non-specific resistance to stress without significant side effects. Rhodiola has been used in traditional Siberian medicine for centuries; it entered Western sports science through Soviet military medical research programs on adaptogens in the 1960s–70s.
The 2025 Meta-Analysis: 26 RCTs, 668 Participants
Wang X., Yang X., Gao Z., Zeng J., and Liu Y. (Frontiers in Nutrition, 2025) conducted a systematic review and meta-analysis of randomized controlled trials published before March 20, 2025. The final analysis included 26 RCTs with 668 healthy volunteers (mean age 22.0 ± 10.7 years); mean supplementation duration was 33 days. Participants included trained and untrained adults of both sexes.
How Does Rhodiola Affect Endurance Performance?
Across 11 trials included in the meta-analysis, Rhodiola significantly improved VO2max (ES = 0.32; p < 0.01). Time to volitional exhaustion increased across 7 trials (ES = 0.38; p < 0.05), and time-trial performance improved across 5 trials (ES = −0.40; p < 0.05). By Cohen's scale: effect sizes are small to moderate — noticeable but not dramatic.
Subgroup analysis revealed that doses above 600 mg/day produced greater VO2max gains; in trained participants, creatine kinase reduction was more pronounced than in untrained individuals.
What Happens to Markers of Muscle Damage?
Across 9 trials measuring post-exercise creatine kinase (CK), Rhodiola reduced it with ES = −0.84 (p < 0.01) — a medium-to-large effect. Serum lactate decreased across 7 trials (ES = −0.87; p < 0.05).
Antioxidant Activity: What Do the Numbers Show?
Malondialdehyde (MDA) — a marker of lipid peroxidation — decreased with ES = −1.21 (p < 0.001) across 6 trials; this is a large effect. Superoxide dismutase (SOD) increased (ES = 1.16; p < 0.01) across 7 trials. Total antioxidant capacity (TAC) increased with ES = 0.59 (p < 0.05) across 6 trials.
Importantly: no significant effect on the inflammatory markers IL-6 and CRP was detected. Rhodiola's mechanism is antioxidant, not classically anti-inflammatory.
How Does This Work at the Cellular Level?
The proposed pathway: rosavins and salidroside activate the antioxidant system via the Nrf2 pathway, thereby reducing lipid peroxidation in muscle cells. In parallel, they appear to attenuate the hypothalamic-pituitary-adrenal axis response to exercise stress. Direct RCTs measuring cortisol were not pooled in this meta-analysis — that represents a separate line of evidence.
What Are the Limitations of This Data?
The mean age of participants in the pool was 22 years; extrapolation to age groups 45+ requires caution. A supplementation duration of 33 days is insufficient for understanding long-term effects and safety. Standardization for rosavin and salidroside content varies between manufacturers — results are not always transferable from one product to another. Some trials in the pool are small. Publication bias in favor of positive results cannot be excluded.
- Standardized extract 200–600 mg/day (at least 3% rosavins and 1% salidroside) — the range studied in most included RCTs. At doses above 600 mg, VO2max gains were greater in subgroup analysis, but long-term safety data at these doses are lacking.
- Best-studied context — endurance exercise: running, cycling, rowing. Data for strength training are limited.
- Rhodiola does not replace sleep and recovery. Data on inflammation (IL-6, CRP) are non-significant — the supplement is not an "anti-inflammatory" in the classical sense.
- For anxiety disorders, bipolar disorder, or use of MAO inhibitors — only after consulting a physician. Rhodiola may potentiate the effects of certain psychotropic medications.
- Results were obtained in young adults. Prior to use by individuals over 45 or those with chronic conditions, a risk assessment with a physician is recommended.
Frequently Asked Questions
Sources
- Wang X., Yang X., Gao Z., Zeng J., Liu Y. «The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis». Frontiers in Nutrition. 2025. DOI: 10.3389/fnut.2025.1645346. pmc.ncbi.nlm.nih.gov/articles/PMC12507841
- Lucius K. «Rhodiola rosea: Clinical Evidence for Adaptogenic and Ergogenic Effects». Integrative Cancer Therapies. 2024. journals.sagepub.com/doi/10.1089/ict.2024.56827.luc